Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Comment by SamV21on Feb 07, 2022 1:41pm
76 Views
Post# 34405526

RE:ARDS-003 is going to be a successful drug

RE:ARDS-003 is going to be a successful drug
  • Approximately 40+ key companies are developing Sepsis therapies. These companies are Cidara Therapeutics, Vivacelle Bio, Shaperon, Karyopharm Therapeutics, SciClone Pharmaceuticals, Asahi Kasei Pharma, Sanofi, Shionogi, Revimmune, Inotrem, Enlivex Therapeutics, Abionyx, and others have their Sepsis drug candidates in the under different phases of clinical development.  
  • Rezafungin (formerly known as CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and prophylaxis of invasive fungal infections due to Candida Aspergillus and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.
  • Funny no mention of Tetra Bio Pharma as usual , Tetra has wishfull thinking good luck, left in the dust and paid for it.
<< Previous
Bullboard Posts
Next >>